NeoImmuneTech Licenses IL-7 Therapy NT-I7 to Tolerance Bio in Deal Worth Up to $260 Million
核心洞察
NeoImmuneTech (搜索) signed its first out-licensing deal since its 2021 market debut, granting Tolerance Bio (搜索) rights to develop NT-I7 for thymus-related indications.
The agreement includes up to $260 million in milestone payments, 4% equity in Tolerance Bio (搜索), and tiered royalties on net sales.
Tolerance Bio (搜索) plans to initiate Phase II studies of efineptakin alfa in thymic function enhancement, with HIV (搜索) immunological non-response among initial indications.
NeoImmuneTech (搜索) (KOSDAQ: 950220.KQ) has signed a licensing agreement with Philadelphia-based Tolerance Bio (搜索) worth up to $260 million (approximately 366.9 billion won), marking the South Korean company's first out-licensing deal since its stock market debut in 2021. Under the agreement, announced in a regulatory filing on the 19th, Tolerance Bio receives exclusive rights to develop and commercialize the drug candidate NT-I7 for indications related to dysfunction of the thymus, one of the body's immune organs.
The aim of the collaboration is to protect, maintain, restore, and enhance thymus function in people with human immunodeficiency virus (HIV (搜索)) infection and others, and to reconstitute thymus-dependent T-cell immunity. NeoImmuneTech (搜索) CEO Kim Tae-kyung described the deal as significant, noting that it expands NT-I7's applications into a new treatment area while raising its development value together with a partner that has expertise in that field.
Deal Structure and Financial Terms
As an upfront payment, NeoImmuneTech (搜索) will receive shares equal to 4% of Tolerance Bio (搜索)'s fully diluted equity. Milestone payments tied to clinical development and sales targets total up to $260 million (about 366.9 billion won). If commercialization succeeds, the company will additionally receive running royalties at agreed rates based on annual net sales.
The inclusion of equity consideration alongside milestones and royalties is structurally notable for a deal involving a seed-stage licensee. This arrangement, in which NeoImmuneTech (搜索) receives Tolerance Bio (搜索) equity in addition to downstream economics, is more common in early-stage collaborations where the licensor takes a long-term stake in the licensee's success rather than maximizing upfront cash.
The Asset: Efineptakin Alfa (NT-I7)
Efineptakin alfa is described by NeoImmuneTech (搜索) as a next-generation fusion protein with two IL-7 moieties stabilized by N-terminal engineering and fused to the company's hyFc long-acting platform, designed to extend half-life and sustain IL-7 activity. The molecule has been evaluated in more than 800 subjects across 15 clinical studies, generating safety, tolerability, and pharmacologic data that the companies said support further development. No specific trial identifiers or efficacy data were disclosed in the announcement.
Tolerance Bio's Clinical Plans
The deal marks Tolerance Bio (搜索)'s transition from a preclinical platform company into clinical-stage operations. The firm was founded in October 2024 with a $17.2 million seed round and later expanded to $20.2 million. The company said it plans to initiate Phase II studies evaluating efineptakin alfa in thymic function enhancement, with HIV (搜索) immunological non-response among the initial indications.
The license covers "certain thymus-related indications" rather than all possible uses of the molecule, and spans the Americas and Europe. NeoImmuneTech (搜索) retains rights outside the Americas and Europe.
Scope and Strategic Positioning
Key areas that NeoImmuneTech (搜索) is developing on its own, including cancer immunotherapy, are excluded from the scope of the agreement. This means the company will continue clinical trials to verify NT-I7's therapeutic effect as a cancer immunotherapy, preserving its ability to continue pursuing oncology, CAR-T combination, and other non-thymic programs independently or with other partners.
The efineptakin alfa license represents the first clinical-stage asset in what Tolerance Bio (搜索) describes as a multi-modality thymus-focused pipeline that also includes thymus-targeting mRNA and cell therapies. In September 2025, the company announced an R&D collaboration with ZipCode Bio to advance targeted thymus therapeutics, and in October 2025 it published preclinical data showing that implanted iPSC-derived thymic organoids enabled in vivo positive selection of human T cells and tumor burden reduction in a melanoma model.